Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
11/2005
11/17/2005US20050256140 Condensed pyridines and pyrimidines with tie2 (tek) activity
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050256092 Antipsoriatic agent
11/17/2005US20050256084 Administering stachyose to treat atopic dermatitis; can be added to medicine, food and beverage
11/17/2005US20050256079 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
11/17/2005US20050256066 Fredericamycin derivatives
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255102 binds to alpha v beta 6 and not other alpha v integrins or non-specific integrins; inhibits the binding of alpha v beta 6 to latency associated peptide with an IC50 value lower than that of 10D5 and binds alpha v beta 6 in manner that does not distinguish between the use of Ca2+/Mg2+ and Mn2+ for cation
11/17/2005US20050255076 Therapeutic cream for dermatitis
11/17/2005DE10392697T5 Herstellung und Standardisierung von immunmodulierenden Peptid-verknüpften Glucanen mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor Preparation and standardization of immunomodulating peptide-linked glucans with detectable oral absorbability from Coriolus Versicolor
11/17/2005CA2566398A1 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
11/17/2005CA2566184A1 Imidazopyridine compound
11/17/2005CA2563955A1 Novel biaromatic compounds which activate ppar.gamma.-type receptors, their process of preparation and their usein cosmetic or pharmaceutical compositions
11/16/2005EP1595936A1 Antioxidative composition and composition for external use
11/16/2005EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
11/16/2005EP1594897A2 Use of il-6 antagonists in combination with steroids to enhance apoptosis
11/16/2005EP1594895A1 Growth factor complexes and modulation of cell migration and growth
11/16/2005EP1594841A1 Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
11/16/2005EP1594837A1 Compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions
11/16/2005EP1594526A1 Methods for promoting wound healing and/or reducing scar formation
11/16/2005EP1594522A1 Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases
11/16/2005EP1594496A2 Novel therapeutic method and compositions for topical administration
11/16/2005EP1594486A2 Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same
11/16/2005EP1594462A1 Surgical implant compprising an anabolic and a corticosteroid
11/16/2005EP1594454A1 Film forming hydroalcoholic foam
11/16/2005EP1594364A1 Skin composition
11/16/2005EP1496895B1 Use of cyclopamine in the treatment of psoriasis and other skin disorders
11/16/2005EP1492795B1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
11/16/2005EP1487472A4 Stabilization of hypoxia inducible factor (hif) alpha
11/16/2005EP1463823A4 Methods of increasing endogenous erythropoietin (epo)
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP1267807B1 The use of prostaglandin F analogs for the preparation of compositions for the treatment of hair loss.
11/16/2005EP1239824B1 Scar treatment composition comprising a silicone mixture
11/16/2005EP1222191B1 Benzodiazepin derivatives, the production and use thereof
11/16/2005EP1220663B1 Superficial therapeutic system for topically applying acetylsalicylic acid, for the treatment of acne-related diseases
11/16/2005EP1212097B1 Enzyme inhibitors
11/16/2005EP1114052B1 4-aminopyrrolopyrimidines as kinase inhibitors
11/16/2005EP0923378B1 Promotion of wound healing by chemically-modified tetracyclines
11/16/2005EP0904099B1 Pharmaceutical formulation containing human growth hormone, histidine and a non-ionic detergent
11/16/2005EP0876395B1 Inhibitors of interleukin-1beta converting enzyme
11/16/2005CN1697836A Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists
11/16/2005CN1697830A 嘧啶衍生物 Pyrimidine derivatives
11/16/2005CN1697828A New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
11/16/2005CN1697655A Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
11/16/2005CN1697645A Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
11/16/2005CN1696300A Arachidonic acid and methods for the production and use thereof
11/16/2005CN1227263C Peptide diagnostic and therapeutic agent for autoimmune diseases
11/16/2005CN1227248C Imidazolidine derivatives, their preparation, and their use as antinflamatory agent
11/16/2005CN1227238C Piperidinyloxy and pyrrolidinyloxyphenyl oxazolidiones as antibacterials
11/16/2005CN1227233C 5-chloro-3-(4-methane sulfonylphenyl)-6-methyl-[2,3'] bipyridine and process for synthesis
11/16/2005CN1227219C Biocidal polymers based on guanidine salts
11/16/2005CN1227212C Method for preparing fatty substance ester and use thereof in pharmaceutics, cosmetics or food industry
11/16/2005CN1227035C Conjugates and method for production thereof, and their use for transporting molecules via biological membranes
11/16/2005CN1227021C Capsule with high cellulose for expelling of toxin and nourishing skin as well as its manufacturing methods
11/16/2005CN1227012C Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
11/16/2005CN1226996C Anti-adiposis composition based on garlic bulb extracts
11/16/2005CN1226991C Turmeric as antiirritant in composition contg. hydroxy acid or retinene derives.
11/16/2005CN1226982C Oil-in-water emulsion comprising micronised biologically active agent and appropriate emulsified system
11/15/2005US6965027 Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
11/15/2005US6965018 Antibodies directed to B7-related polypeptide, BSL-2
11/15/2005US6965010 Polypeptideeptide for use in the treatment of cancer, neovascularization defects, retinopathies, arthritis and psoraisis
11/15/2005US6964980 Method of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substitute indolealkanoic acids
11/15/2005US6964978 Dissolving with crystal growth inihibitos; drying
11/15/2005US6964973 Nonsteroidal agonists and antagonists
11/15/2005US6964972 8-Azabicyclo(3,2,1)oct-2 ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors
11/15/2005US6964967 Substituted pyrido[2,3-d]pyrimidines and methods for their use
11/15/2005US6964965 Corticotropin releasing factor antagonists
11/15/2005US6964960 Indoloquinazolinones
11/15/2005US6964956 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization
11/15/2005US6964955 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
11/15/2005US6964954 Use of DHEA derivatives on keratinous substances
11/15/2005US6964783 Non-solid composition for local application
11/15/2005CA2387517C Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
11/10/2005WO2005106016A1 METHOD OF DETECTING Th1 CELL
11/10/2005WO2005105731A1 Novel crystalline calcium pantothenate
11/10/2005WO2005105126A1 Active oxygen eliminator and moisturizer containing wild watermelon extract
11/10/2005WO2005105121A1 Use of platelets or platelet rich plasma (prp)
11/10/2005WO2005105115A1 Functionalised siloxanes for scar tissue treatment
11/10/2005WO2004069142A8 Anti-candida agents for the treatment of prion diseases
11/10/2005US20050250939 Process for the production of multiple cross-linked hyaluronic acid derivatives
11/10/2005US20050250850 Amino acid composition promoting collagen synthesis
11/10/2005US20050250792 Substituted piperidine compounds useful as modulators of chemokine receptor activity
11/10/2005US20050250758 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
11/10/2005US20050250710 Antiaging composition
11/10/2005US20050250698 Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications
11/10/2005US20050250697 Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications
11/10/2005US20050250695 Combination PDGF, KGF, IGF, and IGFBP for wound healing
11/10/2005US20050250693 Metalloproteinase inhibitors
11/10/2005US20050250196 Recombinant microorganisms expressing an oligosaccharide receptor mimic
11/10/2005US20050249761 Topical composition comprising at least one aryl oxime and bisabolol
11/10/2005US20050249670 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
11/10/2005DE102004017982A1 Composition, useful or cosmetic or medicinal purpose e.g. in the form of mask, comprises collagen (e.g. fish collagen) and carbohydrates (e.g. carboxymethyl cellulose)
11/10/2005CA2565054A1 Functionalised siloxanes for scar tissue treatment
11/10/2005CA2562400A1 Novel phenantridine analogues and their uses as inhibitors of hyperproliferation of t cells and/or keratinocytes
11/10/2005CA2560165A1 Solid pharmaceutical form comprising an ltb4 antagonist
11/09/2005EP1593678A1 Crystal of (23s)-1alpha-hydroxy-27-nor-25-methylenevitamin d3-26,23-lactone and process for producing the same
11/09/2005EP1593379A2 Uses of PPAR-gamma agonists in neutrophil-induced diseases
11/09/2005EP1593373A1 Compositions comprising quaternary ammonium compounds
1 ... 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 ... 1065